<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="908">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05149339</url>
  </required_header>
  <id_info>
    <org_study_id>ZU-IRB #5208/13-2-2019</org_study_id>
    <nct_id>NCT05149339</nct_id>
  </id_info>
  <brief_title>Vitamin D Effect on A Disintegrin-like And Metalloprotease Thrombospondin1 Motif 13&amp; Interleukin 6 in Leukemia</brief_title>
  <official_title>Effect of Vitamin D Status on A Disintegrin-like And Metalloprotease With Thrombospondin Type 1 Motif 13 (ADAMTS13) and Interleukin 6 (IL-6) in Patients With Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zagazig University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zagazig University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Disintegrin-like And Metalloprotease with Thrombospondin type 1 motif 13 (ADAMTS13)&#xD;
      deficiency was incriminated in poor prognosis, high probability of serious complications and&#xD;
      mortality in acute myeloid leukemia (AML) patients. Interleukin 6 (IL-6) produced from AML&#xD;
      blasts decreases Cluster of differentiation 34 positive(CD34+) cells differentiation, and&#xD;
      inhibits the ADAMTS13 actions. Vitamin D &quot;as an Immune-modulator&quot; inhibits the&#xD;
      pro-inflammatory cytokines including IL-6. So, supplementation of vitamin D might help down&#xD;
      regulation of interleukin-6 production.&#xD;
&#xD;
      Aim of the study To evaluate the potential relation between Vitamin D status, ADAMTS13 and&#xD;
      IL-6 in AML patients.&#xD;
&#xD;
      Objectives&#xD;
&#xD;
        1. Assess Vitamin D level in AML patients&#xD;
&#xD;
        2. Assess ADAMTS13 and IL-6 in AML patients&#xD;
&#xD;
        3. Correlate between Vitamin D level and both of ADAMTS13 and IL-6&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      I. Setting The study will be carried out in wards of ZAGAZIG University Hospitals II.&#xD;
      Subjects The study will be conducted on patients with de novo diagnosis with acute myeloid&#xD;
      leukemia III. Inclusion criteria&#xD;
&#xD;
        1. Patient's consent to share in the study&#xD;
&#xD;
        2. Patients' age &gt;18 years&#xD;
&#xD;
        3. Patients with de novo acute myeloid leukemia IV. Exclusion criteria&#xD;
&#xD;
      1. Patients refusing to share in the study 2. Non-Egyptian patients 3. Patients' age &lt; 18&#xD;
      years 4. Pregnant women 5. Patient's with other malignancies 6. Patients with known&#xD;
      congenital thrombotic/ hemorrhagic diseases 7. Patients with Thrombotic Thrombocytopenic&#xD;
      Purpura 8. Patients with auto-immune diseases&#xD;
&#xD;
      V. Study Design This is a Non-randomized control trial I. Sample size up Finding that&#xD;
      ADAMTS13 level in AML patients before treatment is 455+_120 ng/ml versus 570+_100 ng/ml after&#xD;
      treatment, the sample was calculated to be 30 patients, 15 patients in each group by using&#xD;
      (open EPI) at confidence level 95 and power 80 I. Activities Patients attending to ZAGAZIG&#xD;
      University Hospitals. Upon agreement, every patient will be asked to provide written informed&#xD;
      consent according to the Declaration of Helsinki of 1979.&#xD;
&#xD;
      All patients will be subjected to the following:&#xD;
&#xD;
        1. Full History taking through an interview&#xD;
&#xD;
        2. Clinical examination&#xD;
&#xD;
        3. Laboratory investigations including:&#xD;
&#xD;
             1. Complete blood picture ( CBC) using ( Sysmex XS 500)&#xD;
&#xD;
             2. Peripheral blood film examination&#xD;
&#xD;
             3. Erythrocyte sedimentation rate ( Westergren tubes )&#xD;
&#xD;
             4. Prothrombin time, Partial thromboplastin time (Sysmex CS)&#xD;
&#xD;
             5. C-reactive protein , Liver function tests &amp; Kidney function tests (Roche&#xD;
                Diagnostics, Cobas 8000 c702, Switzerland)&#xD;
&#xD;
             6. Hepatitis C virus antibody, Hepatitis B virus surface antigen and Human deficiency&#xD;
                virus antibody&#xD;
&#xD;
             7. Diagnosis of Acute myeloid leukemia according to clinical findings, CBC, peripheral&#xD;
                blood film examination, Bone marrow aspiration, Immunophenotyping (a FACSCAN,&#xD;
                Becton Dickinson, San Jose, California, USA)and Cytogenetic analysis.&#xD;
&#xD;
        4. Measuring IL-6 and ADAMTS13 using (Luminex Corporation, Luminex® 200 trademark , Austin,&#xD;
           USA) before and after induction therapy&#xD;
&#xD;
        5. Measuring Vitamin D serum level using (Roche Diagnostics, Cobas 6000 e 601, Switzerland)&#xD;
           before and after induction therapy and vitamin D supplementation based on its&#xD;
           deficiency.&#xD;
&#xD;
        6. Radiology:&#xD;
&#xD;
             -  Echocardiogram&#xD;
&#xD;
             -  Abdominal ultrasound ( If needed)&#xD;
&#xD;
             -  Chest X-Ray II. Data collection Demographic data of the patients will be recorded&#xD;
                including name, age, sex and residence. In addition, careful history taking and&#xD;
                clinical examination will be done, and data will be registered in special form III.&#xD;
                Statistical analysis Our study will be carried on 30 patients with de novo AML.&#xD;
                Subjects will be divided into (2) groups as regard treatment of Vitamin D&#xD;
                deficiency at the onset of AML diagnosis. Vitamin D therapy will be given to 15&#xD;
                deficient subjects for one month with the recommended doses. All the analytes will&#xD;
                be assayed before and after the induction chemotherapy course. Both of these groups&#xD;
                will be compared statistically using Statistics program smart solution 22 (SPSS22).&#xD;
&#xD;
      Administrative design:&#xD;
&#xD;
      Approval will be asked from ZAGAZIG University Institutional Review Board (IRB).&#xD;
&#xD;
      C. Ethical considerations&#xD;
&#xD;
        1. The study group will be informed about the nature and the purpose of the study and&#xD;
           informed consent will be taken.&#xD;
&#xD;
        2. The study group will not be exposed to any harm or risk.&#xD;
&#xD;
        3. Patient's data will be confidential.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Actual">March 15, 2021</completion_date>
  <primary_completion_date type="Actual">February 1, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(Cholecalciferol 2800 I.U. /ml) Oral drops for Vitamin D deficiency correction</measure>
    <time_frame>Oral daily dose for 28 days</time_frame>
    <description>Using 1ml of Cholecalciferol as daily Oral drops for 28 days to correct the Vitamin D deficiency in acute myeloid leukemia patients.&#xD;
On day 1;The patient is considered deficient with serum Vitamin D level measuring &lt; 20ng/ml using serum samples operated on (Roche Diagnostics, Cobas 6000 e 601, Switzerland) On using the drug for 28 days and measuring the Vitamin D level on the day 28, Vitamin D is considered to be &quot;corrected&quot; with levels &gt; 20 ng/ml</description>
  </primary_outcome>
  <other_outcome>
    <measure>Serum Vitamin D status effect on ADAMTS13 level in AML patients</measure>
    <time_frame>28 days</time_frame>
    <description>Serum Vitamin D (ng/ml) measured using (Roche Diagnostics, Cobas 6000 e 601, Switzerland) on day 1 and day 28 . ADAMTS13 (ng/ml) is measured using (Luminex Corporation, Luminex® 200TM , Austin, USA) on day 1 and day 28 The inter-relation ship will be statistically assessed</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum Vitamin D status effect on IL-6 level in AML patients</measure>
    <time_frame>28 days</time_frame>
    <description>Serum Vitamin D (ng/ml) measured using (Roche Diagnostics, Cobas 6000 e 601, Switzerland) on day 1 and day 28 . IL-6 (PG/ml) is measured using (Luminex Corporation, Luminex® 200TM , Austin, USA) on day 1 and day 28 The inter-relation ship will be statistically assessed</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Vitamin D Deficiency</condition>
  <condition>ADAMTS13</condition>
  <condition>Interleukin 6</condition>
  <arm_group>
    <arm_group_label>Case subgroup with deficient Vitamin D</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Group with deficient Vitamin D &lt; 20 ng/mL No treatment for the Vitamin D deficiency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Case subgroup with deficient Vitamin D + Vitamin D supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group with deficient Vitamin D + Daily oral dose of Cholecalciferol for 28 days for correcting the deficiency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Case subgroup with normal Vitamin D</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Group with normal Vitamin D level &gt; 20 ng/mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol 2800 I.U. ml oral drops</intervention_name>
    <description>(Cholecalciferol 2800 I.U. ml) Oral Drops 15 ml. supplied with a dropper.&#xD;
Composition:&#xD;
Each 1 ml (= 28 drops) of oral solution contains: Vitamin D3 (Cholecalciferol) 2800 I.U., (each drop contains 100 IU of vitamin D3).</description>
    <arm_group_label>Case subgroup with deficient Vitamin D + Vitamin D supplementation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient's consent to share in the study&#xD;
&#xD;
          2. Patients' age &gt;18 years&#xD;
&#xD;
          3. Patients with denovo acute myeloid leukemia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients refusing to share in the study&#xD;
&#xD;
          2. Non-Egyptian patients&#xD;
&#xD;
          3. Patients' age &lt; 18 years&#xD;
&#xD;
          4. Pregnant women&#xD;
&#xD;
          5. Patient's with other malignancies&#xD;
&#xD;
          6. Patients with known congenital thrombotic/ hemorrhagic diseases&#xD;
&#xD;
          7. Patients with Thrombotic Thrombocytopenic Purpura&#xD;
&#xD;
          8. Patients with auto-immune diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dina Ashraf Abdelhady</name>
      <address>
        <city>Cairo</city>
        <state>Madinaty</state>
        <zip>19519</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Liu C, Zhao L, Zhao J, Xu Q, Song Y, Wang H. Reduced ADAMTS-13 level negatively correlates with inflammation factors in plasma of acute myeloid leukemia patients. Leuk Res. 2017 Feb;53:57-64. doi: 10.1016/j.leukres.2016.12.004. Epub 2016 Dec 20.</citation>
    <PMID>28033504</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu C, Han M, Zhao L, Zhu M, Xu Q, Song Y, Wang H. ADAMTS-13 activity reduction in plasma of acute myeloid leukemia predicts poor prognosis after bone marrow transplantation. Hematology. 2019 Dec;24(1):129-133. doi: 10.1080/10245332.2018.1532648. Epub 2018 Oct 16.</citation>
    <PMID>30322352</PMID>
  </results_reference>
  <results_reference>
    <citation>Cohen-Hagai K, Rashid G, Einbinder Y, Ohana M, Benchetrit S, Zitman-Gal T. Effect of Vitamin D Status on Von Willebrand Factor and ADAMTS13 in Diabetic Patients on Chronic Hemodialysis. Ann Lab Med. 2017 Mar;37(2):155-158. doi: 10.3343/alm.2017.37.2.155.</citation>
    <PMID>28029003</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang Y, Leung DY, Richers BN, Liu Y, Remigio LK, Riches DW, Goleva E. Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol. 2012 Mar 1;188(5):2127-35. doi: 10.4049/jimmunol.1102412. Epub 2012 Feb 1.</citation>
    <PMID>22301548</PMID>
  </results_reference>
  <results_reference>
    <citation>Sun X, Cao ZB, Zhang Y, Ishimi Y, Tabata I, Higuchi M. Association between serum 25-hydroxyvitamin D and inflammatory cytokines in healthy adults. Nutrients. 2014 Jan 2;6(1):221-30. doi: 10.3390/nu6010221.</citation>
    <PMID>24451309</PMID>
  </results_reference>
  <results_reference>
    <citation>Sun CF, Zhao X, Han F, Jia Q, Wang L, Lu G, Ding HF. [Changes of ADAMTS13 Activity and TSP1 Level in Patients with Hematologic Malignancies]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Oct;24(5):1294-1298. doi: 10.7534/j.issn.1009-2137.2016.05.002. Chinese.</citation>
    <PMID>27784345</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 20, 2021</study_first_submitted>
  <study_first_submitted_qc>November 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>November 25, 2021</last_update_submitted>
  <last_update_submitted_qc>November 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zagazig University</investigator_affiliation>
    <investigator_full_name>Dina Ashraf Abdelhady</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ADAMTS13</keyword>
  <keyword>Interleukin 6</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

